Trelagliptin Path: From regulatory setbacks in the west to approval in India

Diabetes mellitus represents a substantial socioeconomic burden and has a profound effect on daily living and productivity. Dipeptidyl peptidase-4 (DPP-4) inhibitors are frequently employed in the management of type 2 diabetes, where maintaining long-term glycemic control is vital to prevent or delay macrovascular and microvascular complications. Medication adherence is a crucial element of effective type 2 diabetes management, and minimizing dosing frequency can alleviate the treatment burden and improve patient adherence. The once-weekly administration of trelagliptin, a DPP-4 inhibitor, offers a promising therapeutic strategy, as reduced dosing schedules are often preferred by patients and clinicians. Therefore, trelagliptin can provide new avenues and research areas for the future. This article aims to review the trelagliptin as a once weekly treatment option in patient of type 2 diabetes mellitus However, more research, including clinical trials, should be done to further evaluate this.